Gastric perforation related to concurrent use of nintedanib and ramucirumab

The prevalence of lung cancer in idiopathic pulmonary fibrosis (IPF) patients ranges from 9.8 to 38%. Nintedanib, a small molecule receptor tyrosine kinase inhibitor (TKI) of platelet‐derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Saeko, Murata, Saori, Yoshino, Yudai, Kobayashi, Yosuke, Nakamura, Morio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223100/
https://www.ncbi.nlm.nih.gov/pubmed/30455955
http://dx.doi.org/10.1002/rcr2.383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223100/
https://www.ncbi.nlm.nih.gov/pubmed/30455955
http://dx.doi.org/10.1002/rcr2.383

Ejemplares similares